Sun Pharma Advanced Research Company Ltd (SPARC)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013626)
◆英語タイトル:Sun Pharma Advanced Research Company Ltd (SPARC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013626
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd is a pharma research and drug discovery company that conducts research and and produces drugs. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its product portfolio includes imatinib, nilotinib and dasatinib for the treatment of chronic myelogenous leukemia. SPARC’s preclinical portfolio comprises anti-cancer and anti-inflammatory pipeline candidates. The company also conducts generic research for process development of APIs and formulation development for dosage forms. SPARC is headquartered in Mumbai, Maharashtra, India.

Sun Pharma Advanced Research Company Ltd (SPARC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Sun Pharma Enters into Licensing Agreement with SPARC 10
Sun Pharma Advanced Research Enters into Licensing Agreement with Sun Pharma 11
Equity Offering 12
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 12
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 13
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 14
Sun Pharma Advanced Research Company Ltd – Key Competitors 16
Sun Pharma Advanced Research Company Ltd – Key Employees 17
Sun Pharma Advanced Research Company Ltd – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Mar 31, 2016: Sun Pharma Advanced Research Company Announces Q4 & FY16 Results 19
Feb 03, 2016: Sun Pharma Advanced Research Company Announces Q3 Results 20
Product Approvals 21
Dec 22, 2016: Sun Pharma Advanced Research Company Receives Complete Response Letter from USFDA for Latanoprost NDA 21
Clinical Trials 22
Mar 01, 2017: Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting 22
Jan 04, 2017: Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera for Treatment of Dry Eye 23
Oct 01, 2016: Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis 24
May 04, 2016: Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sun Pharma Advanced Research Company Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sun Pharma Enters into Licensing Agreement with SPARC 10
Sun Pharma Advanced Research Enters into Licensing Agreement with Sun Pharma 11
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 12
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 13
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 14
Sun Pharma Advanced Research Company Ltd, Key Competitors 16
Sun Pharma Advanced Research Company Ltd, Key Employees 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sun Pharma Advanced Research Company Ltd (SPARC)-製薬・医療分野:企業M&A・提携分析(Sun Pharma Advanced Research Company Ltd (SPARC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆